Ozempic Side Effects: A Complete, Evidence-Based Guide

Ozempic vs. Wegovy: Two Semaglutide Products, Different Indications

Ozempic (semaglutide injection) is FDA-approved for glycemic control in adults with type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established heart disease. It is manufactured by Novo Nordisk; Nuv is not affiliated with Novo Nordisk. Ozempic is available in doses of 0.5 mg, 1 mg, and 2 mg administered once weekly.

Wegovy is a separate, higher-dose formulation of semaglutide (2.4 mg once weekly) that is FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Although weight loss is a common reason Ozempic is used off-label, the FDA-approved medication for obesity is Wegovy, not Ozempic. These are distinct products with different prescribing information and dosing pens.

Important: Compounded semaglutide is not FDA-approved. It was not studied in the SUSTAIN or STEP clinical trials that established the safety and efficacy of Ozempic and Wegovy. The FDA has raised concerns about variability in purity, potency, and sterility in compounded versions. There is no assurance that a compounded product will perform the same as or be as safe as an FDA-approved branded medication.

Common Side Effects at a Glance

The SUSTAIN clinical trial program—eight phase 3 trials enrolling thousands of adults with type 2 diabetes—identified gastrointestinal (GI) effects as the most frequently reported adverse reactions with Ozempic. According to the FDA prescribing information, the common adverse reactions occurring in at least 5% of patients and more often than placebo include:

• Nausea — the most commonly reported side effect across all dose levels
• Diarrhea
• Vomiting
• Abdominal pain
• Constipation

These effects are dose-dependent: they occur more frequently and with greater intensity at higher doses and are most prominent when a new dose level is first introduced during the escalation schedule. Other commonly reported reactions include nausea-related decreased appetite, headache, and fatigue. The majority of GI events are mild to moderate in severity.

Nausea: Why It Happens and How It Improves

Nausea is the single most common reason patients contact their provider in the early weeks of Ozempic therapy. It arises through two main mechanisms: semaglutide slows gastric emptying—the rate at which food moves from the stomach into the small intestine—and it activates GLP-1 receptors in the brainstem that regulate satiety and nausea signals.

What the clinical evidence shows:

• Nausea is typically worst in the first one to two weeks after each dose increase and then gradually subsides.
• Most patients find it largely improves within four to eight weeks at a stable dose as the body adapts.
• Eating smaller, lower-fat, lower-sugar meals and avoiding lying down immediately after eating can meaningfully reduce nausea.
• Staying well-hydrated and avoiding foods with strong odors may also help during the adjustment period.
• If nausea is severe, persistent, or prevents adequate caloric intake, contact your provider—a temporary dose pause or slower titration may be appropriate rather than stopping the medication abruptly.

Diarrhea and Constipation

Ozempic affects bowel habits in both directions, and the same patient may experience different effects at different stages of treatment.

• Diarrhea is more common early in treatment and during dose increases, likely related to altered gut motility and faster intestinal transit time in some patients. It is generally self-limiting but can cause dehydration if severe.
• Constipation can emerge or worsen as nausea improves and appetite returns, partly because slowed gastric emptying can extend transit time throughout the GI tract.
• Both effects tend to be more pronounced at higher doses (1 mg and 2 mg) compared to the initial 0.5 mg dose.
• For diarrhea: maintaining adequate fluid and electrolyte intake is the priority. For constipation: increasing dietary fiber and fluid intake is recommended. Discuss with your provider if either persists or becomes disruptive.
• Seek care promptly for severe diarrhea with signs of dehydration (dizziness, dark urine, rapid heart rate) or if you notice blood in your stool.

Injection-Site Reactions and Other Common Effects

Beyond GI symptoms, the FDA label and SUSTAIN trial data identify several other commonly reported effects:

• Injection-site reactions: Redness, bruising, itching, or minor discomfort at the injection site are reported in a small proportion of patients. Rotating the injection site among the abdomen, outer thigh, and upper arm with each weekly injection minimizes these reactions. Ozempic should not be injected into the same spot consecutively.
• Headache: Reported at a higher rate than placebo in trials; typically mild and transient, often improving within the first few weeks.
• Fatigue: Some patients report low energy, particularly during early weeks of treatment or during dose escalation.
• Decreased appetite: A direct pharmacological effect of GLP-1 receptor agonism; while often a desired outcome for people managing weight, it can contribute to nausea and inadequate caloric intake if extreme.
• Hypersensitivity reactions: Rash, urticaria (hives), and pruritus have been reported. Anaphylaxis and angioedema are very rare but are listed in the FDA label. Discontinue and seek emergency care if you develop signs of a serious allergic reaction.

Why Side Effects Peak During Dose Escalation

Ozempic follows a structured titration schedule designed to improve tolerability. The starting dose of 0.25 mg once weekly for four weeks is sub-therapeutic—its purpose is exclusively to allow the body to adjust before reaching an effective dose. The dose is then increased to 0.5 mg weekly, the lowest therapeutic dose. If additional glycemic control is needed, the prescriber may escalate to 1 mg weekly and, if appropriate, to the maximum approved dose of 2 mg weekly.

Each step up in dose triggers a new adjustment period. This is why side effects follow a predictable pattern: they flare briefly around each dose increase and then gradually subside over subsequent weeks. Skipping steps or increasing the dose faster than prescribed significantly increases the severity and duration of GI side effects. Do not adjust your dose on your own—always follow the schedule your provider has prescribed.

Serious but Uncommon Risks: Pancreatitis and Gallbladder Disease

The Ozempic FDA prescribing information includes a warning about acute pancreatitis. Although a definitive causal relationship was not established in the SUSTAIN trials, cases of acute and chronic pancreatitis have been reported in patients receiving semaglutide and other GLP-1 receptor agonists in postmarketing experience. Patients should be counseled to recognize warning signs:

• Severe, persistent abdominal pain, often radiating to the back
• Nausea or vomiting that does not resolve
• Fever accompanying abdominal pain

Discontinue Ozempic and seek prompt medical evaluation if these symptoms develop. Do not restart without explicit guidance from your provider.

Gallbladder disease: Cholelithiasis (gallstones) and cholecystitis have been reported at a higher frequency with semaglutide compared to placebo in clinical trials. Rapid weight loss—a common outcome of GLP-1 therapy—is itself a recognized risk factor for gallstone formation, as reduced cholecystokinin release slows gallbladder emptying. Symptoms to report include sharp right-sided or upper abdominal pain, nausea after meals, fever, or yellowing of the skin or eyes (jaundice).

Boxed Warning: Thyroid C-Cell Tumors

Ozempic carries a boxed warning—the FDA's most serious caution—regarding the risk of thyroid C-cell tumors. In rodent studies at exposure levels similar to those in humans, semaglutide caused dose- and duration-dependent thyroid C-cell tumors, including thyroid carcinoma. It is not known whether Ozempic causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. The relevance of the rodent data to people is currently uncertain.

Because of this risk signal, Ozempic is contraindicated in patients with:

• A personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Patients and providers should be alert to symptoms that could indicate a thyroid tumor: a lump or swelling in the neck, hoarseness, difficulty swallowing, or persistent shortness of breath. Ozempic is also contraindicated in anyone who has had a prior serious hypersensitivity reaction to semaglutide or to any component of the formulation. Routine calcitonin monitoring is not required by labeling but may be considered at your provider's clinical discretion.

Hypoglycemia, Diabetic Retinopathy, and When to Call Your Provider

Hypoglycemia (low blood sugar): Ozempic alone carries a low risk of hypoglycemia in people with type 2 diabetes because it stimulates insulin secretion in a glucose-dependent manner—meaning it works much less when blood glucose is already normal or low. However, the risk increases substantially when Ozempic is combined with insulin or a sulfonylurea (such as glipizide or glimepiride). Your provider may reduce the dose of those medications when Ozempic is started. Recognize the symptoms: shakiness, sweating, confusion, rapid heartbeat, and hunger.

Diabetic retinopathy complications: In the SUSTAIN-6 cardiovascular outcomes trial, diabetic retinopathy complications occurred in 3.0% of patients receiving semaglutide versus 1.8% receiving placebo—a statistically significant difference. This finding is thought to be associated with the rapid lowering of HbA1c in patients with pre-existing, poorly controlled retinopathy, a phenomenon also observed with the initiation of intensive insulin therapy. Patients with a history of diabetic retinopathy should discuss this risk with their provider before starting Ozempic; more frequent ophthalmology monitoring may be appropriate.

Call your provider or seek emergency care if you experience any of the following:

• Severe or persistent abdominal pain, especially if radiating to the back (possible pancreatitis)
• Symptoms of low blood sugar if you are also on insulin or a sulfonylurea
• New or worsening vision changes
• A lump or swelling in the neck, persistent hoarseness, or difficulty swallowing
• Signs of a serious allergic reaction: hives, facial or throat swelling, difficulty breathing
• Right upper abdominal pain, fever, or jaundice (possible gallbladder disease)